Eli Lilly

It's Wait Until Next Year for These Drugmakers

Fool.com (Free subscription) | yesterday

Drugs from AstraZeneca and Eli Lilly face delays because of the FDA.

Eli Lilly withdraws Cymbalta application

News & Observer (Free subscription) | 29/11/2008

Drugmaker Eli Lilly and Co. withdrew an application to have its antidepressant Cymbalta approved as a treatment for chronic pain, but the company said Friday it will apply again in 2009.

• Lilly withdraws Cymbalta chronic pain application - Seattle Post-Intelligencer
• Lilly withdraws Cymbalta chronic pain application - Miami Herald
• See the 11 articles on the same subject

Drug Company Withdraws Application

InformedTrades (Free subscription) | 29/11/2008

Eli Lilly withdrew its application for approval of the antidepressant Cymbalta as a treatment for chronic pain, after regulators questioned whether...

Movers: Eli Lilly, STMicro, Panasonic, Watson Pharma

Business Week (Free subscription) | 28/11/2008

Movers: Eli Lilly, STMicro, Panasonic, Watson PharmaPlus more stocks making headlines in Friday's market From Story Tools CALLON PETROLEUM CO. () Down 4.98 to 2.25 Callon will suspend operations underway to develop the Entrada Field located on the Garden Banks 782 Block in the deepwater of the Gulf of Mexico. The Entrada Field is owned 50% by a subsidiary of Callon, which is the operator. Says "significantly"...

Eli Lilly: Well Poised for Long Term Growth

SeekingAlpha.com (Free subscription) | 26/11/2008

Eli Lilly (LLY), a US$36.47B firm, founded in 1876, manufactures and sells products in two business segment – Pharmaceutical Products and Animal Health Business Segment. It sells its products in US and in 135 other countries. Total global market size for pharmaceutical products alone is about US$650BN, in which US accounts for 43% -approximately about US$279.5BN market. This market is expected to...

TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel

PR News Wire (Free subscription) | 25/11/2008

LA JOLLA, Calif. /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: ) today announced that it has purchased from Eli Lilly & Company a reduction in certain royalty amounts that may become payable to Eli Lilly on net sales of TorreyPines' clinical-stage compounds NGX426 and tezampanel, should either or both gain regulatory approval. Specifically, the top tier royalty rate will be reduced three...

Fitch cuts Eli Lilly to 'A+' on ImClone acquisition

Market Watch (Free subscription) | 24/11/2008

SAN FRANCISCO (MarketWatch) -- Fitch Ratings on Monday lowered Eli Lilly and Co.'s issuer default rating to A+ from AA and its short-term IDR to F1 from F1+. The downgrade is due to the the incremental debt needed to complete $6.5-billion buyout of ImClone Systems . "Fitch believes that the increased leverage heightens the sensitivity of Eli Lilly's credit profile while the company encounters its...

• Fitch Downgrades Eli Lilly & Co.'s IDR to 'A+'; Outlook Stable - Business Wire

Zacks Analyst Blog Highlights: Huntington Bancshares Inc., United Therapeutics Corp., Eli Lilly & Co., Siemens AG and PMI Group Inc.

Business Wire (Free subscription) | 24/11/2008

CHICAGO--(BUSINESS WIRE)--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.

Moody's cuts Eli Lilly on ImClone acquisition

Market Watch (Free subscription) | 21/11/2008

SAN FRANCISCO (MarketWatch) -- Moody's Investors Service on Friday downgraded Eli Lilly's long-term rating to A1 from Aa3 and affirmed its Prime-1 short-term rating. The cut is in response to Lilly's tender offer for the shares of ImClone Systems . "Although the ImClone acquisition creates favorable long term opportunities, Lilly's former Aa3 rating could no longer be supported because of higher financial...

WWMR Announces Pain Clinic Physicians' Most Appreciated Companies: Pfizer, Eli Lilly and Endo Phar..

EuroInvestor.co.uk (Free subscription) | 20/11/2008

SAN FRANCISCO, Nov. 20 /PRNewswire/ -- WWMR, Inc., the marketing research leader in pain, announces results of the first annual "Most Appreciated Pain Drug Company Survey". The top .. - Read more

WWMR Announces Pain Clinic Physicians' Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals

PR News Wire (Free subscription) | 20/11/2008

1. Provides insights from a 10,000 pain-patient database; 2. Understanding drug use for 27 different pain conditions; 3. Monitor uptake of NEW pain drugs; 4. Track reasons for pain drug discontinuations; 5. Examine in-office (IV, injectable, oral and topical) pain drug administrations; 6. Know all the pain drugs a given chronic pain patient is taking; 7. Analyze pain drug detailing & detailing...

Elan hires ex-Lilly exec Paya as new prez

Fiercebiotech (Free subscription) | 20/11/2008

After hunting the biopharma world for more than a year, Ireland's Elan has hired former Eli Lilly exec Carlos Paya as its new president. Paya will be in charge of the company's scientific, clinical and medical initiatives. Chief Scientific Officer Dale Schenk and Chief Medical Officer Ivan Lieberburg will both report to him. Paya had been vice president of Lilly Research Laboratories and global leader...

Lilly inks data management deal with Icon

Fiercebiotech (Free subscription) | 20/11/2008

Icon has won a contract to handle Eli Lilly's clinical data management business outside the United States. The agreement spans more than three dozen countries but excludes the U.S. and Japan. Ireland-based Icon provides outsourced development services to the pharma, biotech medical device industries. Financial terms of the deal were not disclosed. The move is part of Lilly's ongoing strategy to have...

Elan taps Lilly's Carlos Paya president

Market Watch (Free subscription) | 20/11/2008

TEL AVIV (MarketWatch) -- Elan Corp., the Dublin biotech firm, named Carlos Paya president, with responsibility for for leading the company's scientific, clinical and medical initiatives, as well as its commercial and marketing functions. Paya, a medical doctor, joins Elan from Eli Lilly & Co., the Indianapolis drugmaker, where he'd been vice president of Lilly Research Laboratories and global leader...

Senator Tom Daschle to Head HHS

Adventures in Autism (Free subscription) | 20/11/2008

...and this may be good for our kids. Daschle fought the Eli Lilly rider in the Homeland Security Bill and fought the anthrax vaccine that was harming military personnel. From David Kirby's HuffPo piece today: By nominating Tom Daschle to head up the agency, President Elect Obama has selected a man who has demonstrated an unflinching willingness to question vaccine safety, and to fight for the rights...

• David Kirby: Tom Daschle - Friend to Many Autism Families - The Huffington Post